IDL Diagnostics (IDLDX) Q3 2026 earnings summary

Executive summary

• Q3 revenue was SEK 11.1m, near the prior-year SEK 11.4m, while net loss narrowed to SEK 1.7m from SEK 3.1m; improved gross margin and operational efficiency supported earnings.

• 9M revenue reached SEK 42.4m versus SEK 36.8m, and net loss improved to SEK 1.6m from SEK 10.7m.

Financial highlights

• Q3 gross profit was SEK 6.65m versus SEK 5.19m; gross margin rose to 60.1% from 45.6%, attributed to efficiency initiatives and favorable currency effects.

• 9M gross profit was SEK 26.34m versus SEK 18.10m; gross margin increased to 62.2% from 49.1%.

• Q3 operating loss improved to SEK 1.75m from SEK 3.03m; 9M operating loss narrowed to SEK 1.62m from SEK 10.58m.

• 9M operating expenses were SEK 28.29m versus SEK 27.75m; development expenses represented 33% of the total versus 35% YoY.

Outlook and guidance

• Focus remains on expanding in existing and new markets, advancing commercial initiatives toward launch, and combining growth with a path to profitability.

• China UBC CLIA and TK1 CLIA launch preparations continue alongside clinical studies at several hospitals.

• Concile Global completed a European pilot evaluation with good results and registration, enabling future sales.